Clinical and functional features of bronchial asthma AMONG MALE ADOLESCENTS

The study is aimed at studying the clinical and functional features of BA in young men of military age. Methods. A total of 346 men aged 16–28 years (mean age 18 ± 1.7) were examined. The examination protocol corresponded to the algorithm “Medical Examination of Young Men and Draftees with Bronchial Asthma” in 2008. All patients underwent a general clinical and specific allergological examination, a functional lung examination assessing the reversibility of bronchial obstruction. Results. The diagnosis of BA was confirmed in 283 patients, and newly diagnosed in 23 (8.1%) patients. The mild BA was identified in 277 (97.9%) young men. The majority of patients - 240 (84.8%) - were in the remission phase of the disease, and 5 (1.8%) of them had a sustained remission. Allergic BA was diagnosed in the absolute majority of the examined - 261 (92.2%) people, and predominantly mild intermittent BA in 209 patients (73.8%). Symptoms of allergic rhinitis were reported by 198 (70%) patients with allergic BA and 85 (30%) patients with mixed asthma. House dust, library dust were the most common allergens. 68.2% of patients had the burdened heredity of BA and/or atopy. Most of the examined (79.9%) showed no significant changes in the respiratory function, however, 172 (60.8%) patients showed positive results of the β2-agonist test. At the time of the examination, 56 (19.8%) patients received antiasthma basic therapy, the other used only bronchodilators. Replacement of short-acting bronchodilator monotherapy for a combination of above bronchodilator and inhaled corticosteroids as an adjuvant therapy for stage 1 or 2 GINA patients ensures the early and regular administration of the baseline drug and eliminates the problem of excessive dependence on fast-acting bronchodilators. Conclusion The allergic phenotype of the disease with a predominance of milder form dominates in adolescents with asthma. Treatment with a fixed combination of beclomethasone salbutamol 250 μg/100 μg (SabaComb®) can increase compliance, improve the efficacy of the therapy and reduce the risk of BA exacerbations.

1. Nenasheva N.M. New possibilities of treatment of mild asthma. Medical advice. Allergology. 2016;15:3- 10. (In Russ).

2. Avdeev S.A., Aysanov Z.R., Arkhipov V.V. et al. Principles of choice of therapy for patients with mild bronchial asthma. Agreed recommendations of RAACI and RRO. M., 2017.16 s. (In Russ).

3. Goryachkina L.A., Nenasheva N.M., Totikova M.Ch., Shmeleva N.V. Features of bronchial asthma in male adolescents. Pulmonology. 2008;2:15-19. (In Russ).

4. Ненашева Н.М. Контроль бронхиальной астмы у подростков. Педиатрическая фармакология. 2008;5(3):98-103. [Nenasheva N.M. Control asthma in adolescents. Pediatric Pharmacology.2008;5(3):98-103.] (In Russ).

5. Nenasheva N.M. The stages of diagnosis of asthma in adolescents male. Russian Allergology Journal. 2008;6:15-20. (In Russ).

6. Goryachkina LA, Nenasheva N.M., Guseva A.Yu. Medical examination of adolescents and draftees with asthma: a training manual for doctors. M., 2008. 27 s. (In Russ).

7. Paul M., O’Byrne P.M., Jenkins C., Bateman E.D. The paradoxes of asthma management: time for a new approach? Eur Respir J. Sep 2017;50(3):1701103; DOI:10.1183/13993003.01103.

8. Papi A., Canonica G., Maestrelli P. еt al. Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. N Engl J Med 2007;356:2040-2052.